{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T02:53:33Z","timestamp":1790391213902,"version":"4.1.0"},"reference-count":28,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2004,12,20]],"date-time":"2004-12-20T00:00:00Z","timestamp":1103500800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2005,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>BACKGROUND<\/jats:title><jats:p>This Phase II study was designed to evaluate the efficacy and safety of irinotecan in patients with advanced nasopharyngeal carcinoma (NPC).<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS<\/jats:title><jats:p>Patients with disseminated, undifferentiated NPC that progressed during or within 3 months of platinum\u2010based and\/or taxane\u2010based regimen were eligible. Irinotecan at a dose of 100 mg\/m<jats:sup>2<\/jats:sup> was administered on Days 1, 8, and 15 every 28 days, up to a maximum of 6 cycles, until disease progression or the appearance of intolerable toxicity.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>Twenty\u2010eight patients were evaluable for toxicity and response. Patient characteristics were as follows: The median age was 46.5 years (range, 40.3\u201371.6 years), the median number of prior lines of chemotherapy was 2 (range, 1\u20139), the majority of patients (89%) had good Eastern Cooperative Oncology Group performance status (0\u20131), and the majority of patients (82.1%) had \u2265 2 sites of distant metastases. A total of 79 cycles of irinotecan with a median of 3 cycles per patient were administered. Toxicity &gt; Grade 3 included neutropenia in 5 patients (17%), anemia in 5 patients (17%), and diarrhea in 4 patients (14%). The best response outcomes were 4 patients (14%) who achieved partial responses and 1 patient (4%) who achieved stable disease. Global quality\u2010of\u2010life scores were stable during treatment. Using the Kaplan\u2013Meier method, the median progression\u2010free survival was 3.9 months, and the median overall survival was 11.4 months. The partial responders had a durable response (range, 5.7\u201312.2 months).<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS<\/jats:title><jats:p>Results from this trial suggest that irinotecan is an active salvage agent with modest toxicity in patients with advanced NPC who are refractory to platinum\/taxane\u2010based chemotherapy. Studies combining irinotecan with other active agents in the first\u2010line setting are warranted. Cancer 2005. \u00a9 2004 American Cancer Society.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.20802","type":"journal-article","created":{"date-parts":[[2004,12,20]],"date-time":"2004-12-20T11:50:00Z","timestamp":1103543400000},"page":"576-581","source":"Crossref","is-referenced-by-count":50,"title":["Phase II study of irinotecan (CPT\u201011) as salvage therapy for advanced nasopharyngeal carcinoma"],"prefix":"10.1002","volume":"103","author":[{"given":"Donald","family":"Poon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Balram","family":"Chowbay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yin\u2010Bun","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swan\u2010Swan","family":"Leong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eng\u2010Huat","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2005,1,20]]},"reference":[{"key":"e_1_2_5_2_2","series-title":"Cancer Incidence in Five Continents","author":"Parkin DM","year":"1997"},{"key":"e_1_2_5_3_2","volume-title":"Cancer incidence in Singapore, 1993\u20131997","author":"Chia KS","year":"2000"},{"key":"e_1_2_5_4_2","first-page":"19","volume-title":"International histological classification of tumours","author":"Shanmugaratnam K","year":"1978"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.3109\/02841869409098448"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197909)44:3<1029::AID-CNCR2820440335>3.0.CO;2-5"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.annonc.a058703"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1991.9.9.1675"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008342828496"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19940115)73:2<247::AID-CNCR2820730203>3.0.CO;2-7"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1993.312"},{"key":"e_1_2_5_12_2","first-page":"601","article-title":"Cisplatin and 5\u2010fluorouracil continuous infusion for metastatic nasopharyngeal carcinoma","volume":"20","author":"Wang TL","year":"1991","journal-title":"Ann Acad Med Singapore."},{"key":"e_1_2_5_13_2","first-page":"199b","article-title":"The role of salvage chemotherapy in metastatic nasopharyngeal carcinoma","volume":"20","author":"Tay MH","year":"2004","journal-title":"Proc Am Soc Clin Oncol."},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008255220284"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008390929826"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdf002"},{"key":"e_1_2_5_17_2","first-page":"332","article-title":"Apoptosis of nasopharyngeal carcinoma cells induced by topoisomerase I inhibitor","volume":"32","author":"Zhang Q","year":"1997","journal-title":"Zhonghua Er Bi Yan Hou Ke Za Zhi."},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/83.16.1164"},{"issue":"1","key":"e_1_2_5_19_2","first-page":"21","article-title":"CPT\u201011: an original spectrum of clinical activity","volume":"23","author":"Rothenberg ML","year":"1996","journal-title":"Semin Oncol."},{"issue":"7","key":"e_1_2_5_20_2","first-page":"47","article-title":"Topoisomerase I inhibitors in the treatment of head and neck cancer","volume":"15","author":"Murphy BA","year":"2001","journal-title":"Oncology."},{"key":"e_1_2_5_21_2","volume-title":"Handbook for reporting results of cancer treatment","author":"World Health Organisation","year":"1979"},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/85.5.365"},{"key":"e_1_2_5_23_2","volume-title":"The EORTC QLQ\u2010C30 scoring manual","author":"Fayers PM","year":"2001"},{"key":"e_1_2_5_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(89)90015-9"},{"key":"e_1_2_5_25_2","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1201\/9781420035438","volume-title":"Design and analysis of quality of life studies in clinical trials","author":"Fairclough DL","year":"2002"},{"key":"e_1_2_5_26_2","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1177\/030089160308900411","article-title":"Single\u2010agent irinotecan as second\u2010line treatment for advanced gastric cancer","volume":"89","author":"Kanat O","year":"2000","journal-title":"Tumori."},{"key":"e_1_2_5_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/0959-8049(96)00292-4"},{"key":"e_1_2_5_28_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1026207519884"},{"key":"e_1_2_5_29_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1992.10.1.16"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.20802","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.20802","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T12:33:22Z","timestamp":1760272402000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.20802"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,1,20]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2005,2]]}},"alternative-id":["10.1002\/cncr.20802"],"URL":"https:\/\/doi.org\/10.1002\/cncr.20802","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,1,20]]}}}